Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
ZAVICEFTA (ceftazidime and avibactam), for the treatment of patients at high risk of MDR Gram-negative infections with suspected or documented P. aeruginosa, CRE (KPC, OXA-48), and ESBL- and AmpC-producing pathogens1-4.
ZAVICEFTA is indicated for the treatment of adult and paediatric patients aged 3 months and older with the following infections:1*
Complicated intra-abdominal infection (cIAI)
Complicated urinary tract infection (cUTI), including pyelonephritis
Hospital‑acquired pneumonia (HAP), including ventilator‑associated pneumonia (VAP)
Treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. ZAVICEFTA is also indicated for the treatment of infections due to aerobic Gram‑negative organisms in adult patients with limited treatment options.†
*Consideration should be given to the official guidance on the appropriate use of antibacterial agents.1
†Data support the use of ZAVICEFTA in patients with Limited Treatment Options for the treatment of bacteraemia, cSSTI, BSI, meningitis due to KPC and OXA‑48 resistance mechanisms, and MDR Pseudomonas.7-12
Learn more from experts talking about ZAVICEFTA for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1
View Phase III trial results
View safety profile
Access dosing guide
Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.
View patient risk factors
ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.
Learn about coverage
Access our resources for implementation of an Antimicrobial Stewardship Programme and learn more about Pfizer initiatives to fight AMR
cUTI, complicated urinary tract infection; cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase, BSI, bloodstream infection; cSSTI, complicated skin and soft tissue.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020